Guanidinoacetate Methyltransferase (GAMT) Deficiency Sequencing (INACTIVE as of 11/15/21)
Preferred molecular test following biochemical testing suggestive of guanidinoacetate methyltransferase (GAMT) deficiency.
Polymerase Chain Reaction/Sequencing
New York DOH Approval Status
Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).
Transport 3 mL whole blood. (Min: 1 mL)
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable
Background Information for Guanidinoacetate Methyltransferase (GAMT) Deficiency Sequencing:
Characteristics: Intellectual disability and seizure disorder of variable severity. May also include speech / language delays, movement disorder, and behavioral disorders such as autism, hyperactivity, and self-injury.
Incidence: Unknown. More than 50 cases have been described.
Inheritance: Autosomal recessive.
Cause: Pathogenic GAMT gene mutations.
Clinical Sensitivity: Based on limited data, may be as high as 99 percent.
Methodology: Bidirectional sequencing of the entire coding region and intron/exon boundaries of the GAMT gene.
Analytical Sensitivity and Specificity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Regulatory region mutations, deep intronic mutations, and large deletions/duplications will not be detected. Mutations in genes other than GAMT are not evaluated.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2011141||GAMT Sequencing Specimen||31208-2|
|2011142||GAMT Sequencing Interpretation|
- Arginine:Glycine Amidinotransferase (AGAT) Deficiency
- creatine deficiency
- creatine transporter deficiency